Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Financing Activities: 2012-2025

Historic Cash from Financing Activities for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$8.3 million.

  • Enanta Pharmaceuticals' Cash from Financing Activities fell 15.33% to -$8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$26.6 million, marking a year-over-year increase of 3.65%. This contributed to the annual value of -$26.6 million for FY2025, which is 3.65% up from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Cash from Financing Activities stood at -$8.3 million, which was down 29.53% from -$6.4 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Cash from Financing Activities ranged from a high of $199.9 million in Q2 2023 and a low of -$8.3 million during Q3 2025.
  • Over the past 3 years, Enanta Pharmaceuticals' median Cash from Financing Activities value was -$6.4 million (recorded in 2025), while the average stood at $13.1 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 4,751.33% in 2023, then slumped by 31,269.57% in 2024.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Cash from Financing Activities stood at $9.6 million in 2021, then tumbled by 96.88% to $301,000 in 2022, then slumped by 2,541.86% to -$7.3 million in 2023, then surged by 32.16% to -$5.0 million in 2024, then declined by 15.33% to -$8.3 million in 2025.
  • Its Cash from Financing Activities stands at -$8.3 million for Q3 2025, versus -$6.4 million for Q2 2025 and -$6.9 million for Q1 2025.